Literature DB >> 15604294

Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.

Rajal B Shah1, Rohit Mehra, Arul M Chinnaiyan, Ronglai Shen, Debashis Ghosh, Ming Zhou, Gary R Macvicar, Soorynarayana Varambally, Jason Harwood, Tarek A Bismar, Robert Kim, Mark A Rubin, Kenneth J Pienta.   

Abstract

Understanding the biology of prostate cancer metastasis has been limited by the lack of tissue for study. We studied the clinical data, distribution of prostate cancer involvement, morphology, immunophenotypes, and gene expression from 30 rapid autopsies of men who died of hormone-refractory prostate cancer. A tissue microarray was constructed and quantitatively evaluated for expression of prostate-specific antigen, androgen receptor, chromogranin, synaptophysin, MIB-1, and alpha-methylacylCoA-racemase markers. Hierarchical clustering of 16 rapid autopsy tumor samples was performed to evaluate the cDNA expression pattern associated with the morphology. Comparisons were made between patients as well as within the same patient. Metastatic hormone-refractory prostate cancer has a heterogeneous morphology, immunophenotype, and genotype, demonstrating that "metastatic disease" is a group of diseases even within the same patient. An appreciation of this heterogeneity is critical to evaluating diagnostic and prognostic biomarkers as well as to designing therapeutic targets for advanced disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15604294     DOI: 10.1158/0008-5472.CAN-04-2442

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  262 in total

1.  Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.

Authors:  Ziyue Karen Jiang; Makoto Sato; Liu H Wei; Chinghai Kao; Lily Wu
Journal:  Cancer Res       Date:  2011-09-20       Impact factor: 12.701

2.  Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells.

Authors:  Yan Zhou; Jiyuan Yang; Jindřich Kopeček
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

3.  Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.

Authors:  Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

4.  Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.

Authors:  Andreas Varkaris; Paul G Corn; Nila U Parikh; Eleni Efstathiou; Jian H Song; Yu-Chen Lee; Ana Aparicio; Anh G Hoang; Sanchaika Gaur; Lynnelle Thorpe; Sankar N Maity; Menashe Bar Eli; Bogdan A Czerniak; Yiping Shao; Mian Alauddin; Sue-Hwa Lin; Christopher J Logothetis; Gary E Gallick
Journal:  Clin Cancer Res       Date:  2015-08-13       Impact factor: 12.531

5.  Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.

Authors:  Hsueh-Li Tan; Akshay Sood; Hameed A Rahimi; Wenle Wang; Nilesh Gupta; Jessica Hicks; Stacy Mosier; Christopher D Gocke; Jonathan I Epstein; George J Netto; Wennuan Liu; William B Isaacs; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

6.  Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth.

Authors:  Takanori Tsuji; Soichiro Ibaragi; Kaori Shima; Miaofen G Hu; Miki Katsurano; Akira Sasaki; Guo-fu Hu
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

Authors:  Jinlu Dai; Honglai Zhang; Andreas Karatsinides; Jill M Keller; Kenneth M Kozloff; Dana T Aftab; Frauke Schimmoller; Evan T Keller
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

8.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

9.  Integrin α3β1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization.

Authors:  Afshin Varzavand; Justin M Drake; Robert U Svensson; Mary E Herndon; Bo Zhou; Michael D Henry; Christopher S Stipp
Journal:  Clin Exp Metastasis       Date:  2012-12-06       Impact factor: 5.150

10.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.